Myelin oligodendrocyte glycoprotein immunoglobulin G-associated encephalomyelitis

Eliseeva D.D.; Vasilyev A.V.; Shabalina A.A.; Simaniv T.O.; Zakharova M.N.

doi:https://doi.org/10.17116/jnevro202012007213

Close metadata

Recommended articles:

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Postoperative peritonitis: epidemiology, diagnosis, surgical treatment and prognosis. Pirogov Russian Journal of Surgery. 2025;(6):104-111

Artificial intelligence capabilities in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21

Early diagnosis and effective therapy of diabetic polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68

Portopulmonary hypertension. Journal of Respiratory Medicine. 2025;(2):39-44

Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33

Rapidly progressive periodontitis. (A successful experience of eighteen years of observation). Russian Journal of Stomatology. 2025;(2):61-67

Vertebroplasty for pathological vertebral fracture with osteoporosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):67-76

Bacterial vaginosis: modern views. Russian Journal of Clinical Dermatology and Venereology. 2025;(3):261-268

Method of photodynamic action in surgical treatment of local limited peritonitis in the experiment. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):77-86

Abstract:

The article discusses the role of myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) in demyelinating diseases of the central nervous system. Clinical phenotypes of demyelinating syndromes associated with MOG-IgG that are currently included into neuromyelitis optica spectrum disorders (NMOSD) are described. However, it has been shown that encephalomyelitis associated with MOG-IgG (MOG-EM) has certain clinical, radiological, immunological and histopathological features that make it possible to single out these syndromes into a separate nosological form. We provide International recommendations that establish indications for testing MOG-IgG using cell-based assay. We discuss epidemiological issues and classification challenges of the disease. Various approaches to treatment and prevention of relapses of MOG-EM are analyzed.

Keywords:

MOG encephalomyelitis

neuromyelitis optica spectrum disorders

myelin oligodendrocyte glycoprotein immunoglobulin G antibodies (MOG-IgG)

aquaporin-4 immunoglobulin G antibodies (AQP4-IgG)

multiple sclerosis

demyelinating diseases

treatment

Authors:

Eliseeva D.D.

Research Center of Neurology

ORCID: 0000-0003-2173-927X

Vasilyev A.V.

Central Research Institute of Dentistry and Maxillofacial Surgery;
Research Centre for Medical Genetics

SPIN RSCI: 8864-6279
Scopus AuthorID: 56865840500
ResearcherID: C-9338-2013
ORCID: 0000-0002-7169-2724

Shabalina A.A.

Research Center of Neurology

SPIN RSCI: 9414-9068
Scopus AuthorID: 59097027100
ResearcherID: B-2504-2018
ORCID: 0000-0001-9604-7775

Simaniv T.O.

Research Center of Neurology

Zakharova M.N.

Research Center of Neurology

SPIN RSCI: 4277-2860
Scopus AuthorID: 7006679636
ResearcherID: C-4611-2012
ORCID: 0000-0002-1072-9968

Received:

14.05.2020

Accepted:

09.06.2020

Close metadata

References:

Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389:1336-1346. https://doi.org/10.1016/S0140-6736(16)30959-X
Shchepareva ME, Kochergin IA, Tolpeeva OA, Shabalina AA, Zakharova MN. Diagnostic value of antibodies to myelin oligodendrocyte glycoprotein in demyelinating diseases of the central nervous system. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2019;119 (2. Vyp. 2):18-23. (In Russ.). https://doi.org/10.17116/jnevro20191192218
Hoftberger R, Lassmann H. Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neurol. 2017;145:263-283. https://doi.org/10.1016/B978-0-12-802395-2.00019-5
Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, Wildemann B. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2017;264:453-466. https://doi.org/10.1007/s00415-016-8360-4
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. The Lancet. 2004;364:2106-2112. https://doi.org/10.1007/s00415-016-8360-4
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. Igg marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-477.
Lana-Peixoto MA, Callegaro D. The expanded spectrum of neuromyelitis optica: Evidences for a new definition. Arq Neuro-Psiquiatr. 2012;70:807-813. https://doi.org/10.1590/s0004-282x2012001000010
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-815. https://doi.org/10.1016/S1474-4422(07)70216-8
Wingerchuk DM, Banwell B, Bennett, JL, Cabre P, Carroll W, Chitnis T, Weinshenker BG. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-189. https://doi.org/10.1212/WNL.0000000000001729
Belova AN, Bojko AN, Belova EM. Diagnosticheskie kriterii optikomielitassociirovannyh rasstrojstv. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(2):32-40. (In Russ.). https://doi.org/10.17116/jnevro20161162232-40
Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6:383-392. https://doi.org/10.1038/nrneurol.2010.72
Gardinier MV, Amiguet P, Linington C, Matthieu JM. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J Neurosci Res. 1992;33:177-187. https://doi.org/10.1002/jnr.490330123
Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Front Immunol. 2017;8:529. https://doi.org/10.3389/fimmu.2017.00529
Lebar R, Baudrimont M, Vincent C. Chronic experimental autoimmune encephalomyelitis in the guinea pig. Presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the disease. J Autoimmun. 1989;2:115-132. https://doi.org/10.1016/0896-8411(89)90149-2
Weber MS, Derfuss T, Metz I, Bruck W. Defining distinct features of anti- MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018;11. https://doi.org/10.1177/1756286418762083
Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol. 2019;266(5):1280-1286. https://doi.org/10.1007/s00415-018-9122-2
Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder. Neurol. Neuroimmunol. Neuroinflamm. 2015;2(1):e62. https://doi.org/10.1212/NXI.0000000000000062
Simaniv TO, Vasiliev AV, Askarova LSh, Zakharova MN. Neuromyelitis optica and neuromyelitis optica spectrum disorders. Journal of Neurology and Psychiatry im. S.S. Korsakov. 2019;119(10-2):35-48. (In Russ.). https://doi.org/10.17116/jnevro20191191035
Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, Levy M. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66-72. https://doi.org/10.1016/j.msard.2018.07.025
Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, Waters P. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm. 2020;7(2). pii: e674. https://doi.org/10.1212/NXI.0000000000000674
Peschl P, Bradl M, Hӧftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol. 2017;8:529. https://doi.org/10.3389/fimmu.2017.00529
Marta CB, Montano MB, Taylor CM, Taylor AL, Bansal R, Pfeiffer SE. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis. J Biol Chem. 2005;280:8985-8993. https://doi.org/10.1074/jbc.M413174200
Di Pauli F, Berger T. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? Front Immunol. 2018;9:2753. https://doi.org/10.3389/fimmu.2018.02753
Spadaro M, Winklmeier S, Beltrán E, Macrini C, Hӧftberger R, Schuh E, Meinl E. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. 2018;84(2):315‐328. https://doi.org/10.1002/ana.25291
Misu T, Höftberger R, Fujihara K, Wimmer I, Takai Y, Nishiyama S, Lassmann H. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol. 2013;125(6):815-827. https://doi.org/10.1007/s00401-013-1116-7
Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, Aoki M. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry. 2016;87(11):1257-1259. https://doi.org/10.1136/jnnp-2015-312676
de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, Hintzen R. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2019;1352458519845112. https://doi.org/10.1177/1352458519845112
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Wildemann B. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280. https://doi.org/10.1186/s12974-016-0718-0
Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite M, Kleiter I, Chitnis T. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler J. 2015;21:845-853. https://doi.org/10.1177/1352458515572406
van Pelt ED, Wong YYM, Ketelslegers IA, Hamann D, Hintzen RQ. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seroposi-tive cases in the Netherlands. Eur J Neurol. 2015;23(3):580-587. https://doi.org/10.1111/ene.12898
Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128-3138. https://doi.org/10.1093/brain/awx276
Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflammation. 2018;15(1):88. https://doi.org/10.1186/s12974-018-1108-6
Jurynczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, Waters P, Kuker W, Craner M, Weir A. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2017;88:132-136. https://doi.org/10.1136/jnnp-2016-314005
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90:1858-1869. https://doi.org/10.1212/WNL.0000000000005560
Chen L, Chen C, Zhong X, Sun X, Zhu H, Li X. Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China. J Neuroimmunol. 2018;321:83-91. https://doi.org/10.1016/j.jneuroim.2018.05.014
van Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol. 2016;23:580-587. https://doi.org/10.1111/ene.1289
Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG and Wildemann B. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134. https://doi.org/10.1186/s12974-018-1144-2
Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Kuker W, Chandratre S, Vincent A, Palace J. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71:276-283. https://doi.org/10.1001/jamaneurol.2013.5857
Akaishi T, Nakashima I, Takeshita T, Mugikura S, Sato DK, Takahashi T, Nishiyama S, Kurosawa K, Misu T, Nakazawa T. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28-33. https://doi.org/10.1016/j.jneuroim.2016.02.004
Zhou L, Huang Y, Li H, Fan J, Zhangbao J, Yu H, Li Y, Lu J, Zhao C, Lu C. MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients. J Neuroimmunol. 2017;305:19-28. https://doi.org/10.1016/j.jneuroim.2017.01.00
Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, Deluca G, Chandratre S, Leite MI, Vincent A, Palace J: Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140:617-627. https://doi.org/10.1093/brain/aww350
Baumann M, Grams A, Djurdjevic T, Wendel EM, Lechner C, Behring B, Blaschek A, Diepold K, Eisenkolbl A, Fluss J. MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol. 2018;265:845-855. https://doi.org/10.1007/s00415-018-8781-3
Reiber H, Teut M, Pohl D, Rostasy KM, Hanefeld F. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult Scler. 2009;15:1466-1480. https://doi.org/10.1177/1352458509348418
Spadaro M, Gerdes LA, Mayer MC, Ertl-Wagner B, Laurent S, Krumbholz M, Breithaupt C, Hogen T, Straube A, Giese A. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol. 2015;2:295-301. https://doi.org/10.1002/acn3.164
Jarius S, Metz I, Konig FB, Ruprecht K, Reindl M, Paul F, Bruck W, Wildemann B. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016;22:1541-1549. https://doi.org/10.1177/1352458515622986
Konig FB, Wildemann B, Nessler S, Zhou D, Hemmer B, Metz I, Hartung HP, Kieseier BC, Bruck W. Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol. 2008;65:1527-1532. https://doi.org/10.1001/archneur.65.11.1527
Titulaer MJ, Hoftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, Benson LA, Shu H, Irioka T, Hirano M, Dalmau J. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75:411-428. https://doi.org/10.1002/ana.24117
Fan S, Xu Y, Ren H, Guan H, Feng F, Gao X, Ding D, Fang F, Shan G, Guan T. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Mult Scler Relat Disord. 2018;20:144-152. https://doi.org/10.1016/j.msard.2018.01.00
Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e131. https://doi.org/10.1212/NXI.0000000000000131
Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol. 2014;261:17-26. https://doi.org/10.1007/s00415-013-6957-4
Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Fujihara K. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-481. https://doi.org/10.1212/WNL.0000000000000101
Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e131. https://doi.org/10.1212/NXI.0000000000000131
Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22(4):470-482. https://doi.org/10.1177/1352458515593406
Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A, Waters P. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e163. https://doi.org/10.1212/NXI.0000000000000163
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13(1):279. https://doi.org/10.1186/s12974-016-0717-1
Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, Metz I, Blaschek A, Dick A, Brück W, Hohlfeld R, Meinl E, Kümpfel T. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e257. https://doi.org/10.1212/NXI.0000000000000257
Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement — frequency, presentation and outcome. J Neuroinflammation. 2016;13(1):281. https://doi.org/10.1186/s12974-016-0719-z
Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, Phil M, Busch V, Zhou D, Cepok S, Hemmer B. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009;66(6):833-842. https://doi.org/10.1002/ana.21916
Waters P, Fadda G, Woodhall M, O’Mahony J, Brown RA, Castro DA. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol. Epub ahead of print 2019 Sep 23. https://doi.org/10.1001/jamaneurol.2019.2940
Chen C, Liu C, Fang L, Zou Y, Ruan H, Wang Y. Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: a Chinese cohort study. J Neurol Sci. 2019;405:116430. https://doi.org/10.1016/j.jns.2019.116430
Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, Jacob A. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol. 2018;75(1):65-71. https://doi.org/10.1001/jamaneurol.2017.3196
Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol. 2019;266(10):2481-2487. https://doi.org/10.1007/s00415-019-09440-8
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Marignier R. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):1858-1869. https://doi.org/10.1212/WNL.0000000000005560
Titulaer MJ, Hoftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75(3):411-428. https://doi.org/10.1002/ana.24117
Matesanz S, Kotch Ch, Perrone Ch, Waanders AJ, Hill Br, Narula S. Expanding the MOG phenotype. Brainstem encephalitis with punctate and curvilinear enhancement. Neurol Neuroimmunol Neuroinflamm. 2019;6:e619. https://doi.org/10.1212/NXI.0000000000000619
Takasone K, Usuda M, Yoshinaga T, Sekijima Y. Limbic Encephalitis with Anti-myelin Oligodendrocyte Glycoprotein Antibody. Intern Med. 2020. https://doi.org/10.2169/internalmedicine.4216-19
Reindl M, Jarius S, Rostasy K, Berger T. Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they? Curr Opin Neurol. 2017;30:295-301. https://doi.org/10.1097/WCO.0000000000000446
Chen JJ, Flanagan EP, Jitprapaikulsan J, Lopez-Chiriboga ASS, Fryer JP, Leavitt JA, Pittock SJ. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8-15. https://doi.org/10.1016/j.ajo.2018.07.020
Ramanathan S, Mohammad S, Tantsis E, Nguyen TN, Merheb V, Fung V, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson A, Barnett M, Reddel SW, Brilot F, Dale R. on behalf of the Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2008;89:127-137. https://doi.org/10.1136/jnnp-2017-316880
Cortese I, Chaudhry V, So YT, Cantor F. Cornblath DR, Rae-Gant A. Evidence based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294-300. https://doi.org/10.1212/WNL.0b013e318207b1f6
Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, Lim M. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody — associated disease. JAMA Neurol. 2018;75(4):478-487. https://doi.org/10.1001/jamaneurol.2017.4601
Durozard P, Rico A, Boutiere C, Maarouf A, Lacronix R, Cointe S, Audoin B. Comparison of the response to rituximab between MOG- and AQP4-antibody diseases. Ann Neurol. 2020;87(2):256-266. https://doi.org/10.1002/ana.25648
Wallin EF, Jolly EC, Suchanek O, Bradley JA, Espeli M, Jayne DRW. Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers. Blood. 2014;124(17):2666‐2674. https://doi.org/10.1182/blood-2014-07-585976
Kinzel S, Lehmann-Horn K, Torke S, Häusler D, Winkler A, Stadelmann C. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol. 2016;132(1):43‐58. https://doi.org/10.1007/s00401-016-1559-8